オーファンドラッグ（希少疾病用医薬品）の世界市場規模調査＆予測：薬剤タイプ別、売れ筋医薬品別、疾病タイプ別、地域別分析、2023-2030年

オーファンドラッグ（希少疾病用医薬品）は、希少な疾病や病態を治療するために開発された医薬品です。

近年、世界の人口における希少疾病の割合は増加しています。新興国も先進国もこの問題に対処するため、希少疾病の治療薬の発見を奨励し、これらの治療薬が容易に入手できるようにする政策を採用しています。オーファンドラッグ（希少疾病用医薬品）市場は、希少疾病の有病率の上昇や政府の好意的な政策などの要因により拡大しています。

2022年5月のGARD（Genetic and Rare Diseases）情報センターによると、希少疾病は約7,000種類あり、アメリカ人の10人に1人（約3,000万人）が希少疾病に罹患しているといいます。さらに、2021年9月に更新された"GlobalGenes"の統計によると、世界では4億人以上が希少疾病に罹患しています。一般的でない疾病の80%に遺伝的原因が見つかっています。さらに、2022年3月に発表された研究"Rare diseases: maintaining momentum"によると、製薬会社は2021年に希少疾病の研究に総額229億米ドルを投資し、2020年から28％増加しました。その結果、希少疾病の有病率の上昇と研究開発費の増加により、新たな希少疾病治療薬の登場がより期待されるようになり、それが最終的に市場成長の原動力となっています。さらに、希少疾病の新規治療法の開発における研究開発活動の増加や、強力な製品上市活動が、市場に有利な機会を生み出しています。しかし、患者1人当たりの治療費が高く、臨床試験や製品マーケティングのための患者数が限られていることが、2023～2030年の予測期間を通じて市場の成長を阻害しています。

オーファンドラッグ（希少疾病用医薬品）の世界市場調査において考慮した主な地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、ブランド製品の優位性と地域の疾病有病率の増加により、2022年の市場を独占しました。アジア太平洋地域は、市場参入企業の増加、製品開拓のための提携の増加、主要企業の地理的拡大、政府機関や非営利団体の積極的な市場参入などの要因から、予測期間中に大きく成長すると予想されます。

本調査の目的は、近年における様々なセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や薬剤の種類に関する詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• 市場スナップショット
• 世界市場・セグメント別市場推計・予測、2020-2030年
  • オーファンドラッグ（希少疾病用医薬品）市場：地域別、2020-2030年
  • オーファンドラッグ（希少疾病用医薬品）市場：薬剤タイプ別、2020-2030年
  • オーファンドラッグ（希少疾病用医薬品）市場：売れ筋医薬品別、2020-2030年
  • オーファンドラッグ（希少疾病用医薬品）市場：疾病タイプ別、2020～2030年
• 主要動向
• 調査手法
• 調査前提条件

第2章 オーファンドラッグ（希少疾病用医薬品）の世界市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 業界の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 オーファンドラッグ（希少疾病用医薬品）の世界市場力学

• オーファンドラッグ（希少疾病用医薬品）市場のインパクト分析（2020年～2030年）
  • 市場促進要因
    • 希少疾病の増加
    • 有利な政府政策
  • 市場の課題
    • 患者一人当たりの高額治療費
    • 臨床試験および製品マーケティングのための限られた患者数
  • 市場機会
    • 希少疾病の新規治療法開発における研究開発活動の活発化
    • 強力な製品上市活動

第4章 世界のオーファンドラッグ（希少疾病用医薬品）市場の産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 オーファンドラッグ（希少疾病用医薬品）の世界市場：薬剤タイプ別

• 市場スナップショット
• オーファンドラッグ（希少疾病用医薬品）の世界市場：薬剤タイプ別、業績-ポテンシャル分析
• オーファンドラッグ（希少疾病用医薬品）の世界市場：薬剤タイプ別、推定・予測、2020-2030年
• オーファンドラッグ（希少疾病用医薬品）市場、サブセグメント分析
  • 生物学的
  • 非生物学的

第6章 オーファンドラッグ（希少疾病用医薬品）の世界市場：売れ筋医薬品別

• 市場スナップショット
• オーファンドラッグ（希少疾病用医薬品）の世界市場：売れ筋医薬品別、実績 - ポテンシャル分析
• オーファンドラッグ（希少疾病用医薬品）の世界市場、売れ筋医薬品別、推定・予測、2020年～2030年
• オーファンドラッグ（希少疾病用医薬品）市場、サブセグメント分析
  • レブリミド
  • ダルザレックス
  • リツキサン
  • タフィンラー
  • ニンラーロ
  • その他

第7章 オーファンドラッグ（希少疾病用医薬品）の世界市場：疾病タイプ別

• 市場スナップショット
• オーファンドラッグ（希少疾病用医薬品）の世界市場：疾病タイプ別、業績 - ポテンシャル分析
• オーファンドラッグ（希少疾病用医薬品）の世界市場、疾病タイプ別、推定・予測、2020～2030年
• オーファンドラッグ（希少疾病用医薬品）市場、サブセグメント分析
  • 腫瘍
  • 血液
  • 神経
  • 心血管
  • その他の疾病タイプ

第8章 オーファンドラッグ（希少疾病用医薬品）の世界市場：地域別分析

• 主要国
• 主な新興国
• オーファンドラッグ（希少疾病用医薬品）市場、地域別市場スナップショット
• 北米
  • 米国
    • 薬剤タイプ別、推定・予測、2020-2030年
    • 売れ筋医薬品別、推定・予測、2020-2030年
    • 疾病タイプ別、推定・予測、2020-2030年
  • カナダ
• 欧州のオーファンドラッグ（希少疾病用医薬品）市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋のオーファンドラッグ（希少疾病用医薬品）市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカのオーファンドラッグ（希少疾病用医薬品）市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東・アフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Alexion Pharmaceuticals Inc
    • 主要情報
    • 概要
    • 財務（データの入手が可能な場合）
    • 製品概要
    • 最近の動向
  • Bristol-Myers Squibb Company（Celgene Corporation）
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Sanofi S.A
  • Johnson & Johnson Pvt Ltd
  • AstraZeneca Plc

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Orphan Drugs Market, report scope
• TABLE 2. Global Orphan Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Orphan Drugs Market estimates & forecasts by Drug Type 2020-2030 (USD Billion)
• TABLE 4. Global Orphan Drugs Market estimates & forecasts by Top Selling Drugs 2020-2030 (USD Billion)
• TABLE 5. Global Orphan Drugs Market estimates & forecasts by Disease Type 2020-2030 (USD Billion)
• TABLE 6. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Orphan Drugs Market
• TABLE 71. List of primary sources, used in the study of global Orphan Drugs Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Orphan Drugs Market, research methodology
• FIG 2. Global Orphan Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Orphan Drugs Market, key trends 2022
• FIG 5. Global Orphan Drugs Market, growth prospects 2023-2030
• FIG 6. Global Orphan Drugs Market, porters 5 force model
• FIG 7. Global Orphan Drugs Market, pest analysis
• FIG 8. Global Orphan Drugs Market, value chain analysis
• FIG 9. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Orphan Drugs Market, regional snapshot 2020 & 2030
• FIG 15. North America Orphan Drugs Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Orphan Drugs Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Orphan Drugs Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Orphan Drugs Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Orphan Drugs Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Orphan Drugs Market is valued approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Orphan drugs, also known as orphan medicinal products, are pharmaceutical drugs developed to treat rare diseases or conditions. The prevalence of rare diseases among the world's population has grown recently. Both emerging and industrialized nations have adopted policies to address this issue that encourage the discovery of medications for uncommon diseases and ensure that these medications are readily available. The Orphan Drugs market is expanding because of factors such as rising prevalence of rare diseases and favorable government policies.

According to the Genetic and Rare Diseases (GARD) Information Centre in May 2022, there are around 7,000 rare diseases, and one in ten Americans (nearly 30 million individuals) have one. Furthermore, according to statistics from "GlobalGenes" that was updated in September 2021, more than 400 million people globally are affected by uncommon diseases. Inherent genetic causes for 80% of uncommon disorders have been found. Furthermore, according to the study "Rare diseases: maintaining momentum" published in March 2022, drug companies invested USD 22.9 billion in total in research on rare disorders in 2021, a 28% increase from 2020. As a result, there are more prospects for new orphan medications due to rising prevalence and rising research and development spending on uncommon disease, which is ultimately driving the market growth. In addition, increasing research and development activities in the development of new therapies for rare diseases and strong product launches activities is creating a lucrative opportunity to the market. However, high per patient treatment cost and limited patient pool for clinical trials and product marketing stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Orphan Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

• Alexion Pharmaceuticals Inc
• Bristol-Myers Squibb Company (Celgene Corporation)
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Sanofi S.A
• Johnson & Johnson Pvt Ltd
• AstraZeneca Plc

Recent Developments in the Market:

• In June 2022, The Food and medicine Administration (FDA) has designated ALX Oncology Holdings Inc.'s evorpacept, a next-generation CD47 blocker, as an orphan medicine for the treatment of acute myeloid leukaemia (AML).
• In March 2021, The Food and Drug Administration has granted orphan drug classification to Intellia Therapeutics' CRISPR-edited T cell receptor (TCR) T-cell therapy for the treatment of acute myeloid leukaemia (AML).

Global Orphan Drugs Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drug Type, Top Selling Drugs, Disease Type, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Typeofferings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

• Biological
• Non-biological

By Top Selling Drugs:

• Revlimid
• Darzalex
• Rituxan
• Tafinlar
• Ninlaro
• Other

By Disease Type:

• Oncology
• Hematology
• Neurology
• Cardiovascular
• Other Disease Types

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Orphan Drugs Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Orphan Drugs Market, by Drug Type, 2020-2030 (USD Billion)
  • 1.2.3. Orphan Drugs Market, by Top Selling Drugs, 2020-2030 (USD Billion)
  • 1.2.4. Orphan Drugs Market, by Disease Type, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Orphan Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Orphan Drugs Market Dynamics

• 3.1. Orphan Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising Prevalence of Rare Diseases
    • 3.1.1.2. Favorable Government Policies
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Per Patient Treatment Cost
    • 3.1.2.2. Limited Patient Pool for Clinical Trials and Product Marketing
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Increasing research and development activities in the development of new therapies for rare diseases
    • 3.1.3.2. Strong Product Launches activities

Chapter 4. Global Orphan Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Orphan Drugs Market, by Drug Type

• 5.1. Market Snapshot
• 5.2. Global Orphan Drugs Market by Drug Type, Performance - Potential Analysis
• 5.3. Global Orphan Drugs Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
• 5.4. Orphan Drugs Market, Sub Segment Analysis
  • 5.4.1. Biological
  • 5.4.2. Non-biological

Chapter 6. Global Orphan Drugs Market, by Top Selling Drugs

• 6.1. Market Snapshot
• 6.2. Global Orphan Drugs Market by Top Selling Drugs, Performance - Potential Analysis
• 6.3. Global Orphan Drugs Market Estimates & Forecasts by Top Selling Drugs 2020-2030 (USD Billion)
• 6.4. Orphan Drugs Market, Sub Segment Analysis
  • 6.4.1. Revlimid
  • 6.4.2. Darzalex
  • 6.4.3. Rituxan
  • 6.4.4. Tafinlar
  • 6.4.5. Ninlaro
  • 6.4.6. Other

Chapter 7. Global Orphan Drugs Market, by Disease Type

• 7.1. Market Snapshot
• 7.2. Global Orphan Drugs Market by Disease Type, Performance - Potential Analysis
• 7.3. Global Orphan Drugs Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
• 7.4. Orphan Drugs Market, Sub Segment Analysis
  • 7.4.1. Oncology
  • 7.4.2. Hematology
  • 7.4.3. Neurology
  • 7.4.4. Cardiovascular
  • 7.4.5. Other Disease Types

Chapter 8. Global Orphan Drugs Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Orphan Drugs Market, Regional Market Snapshot
• 8.4. North America Orphan Drugs Market
  • 8.4.1. U.S. Orphan Drugs Market
    • 8.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Top Selling Drugs breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Disease Type breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Orphan Drugs Market
• 8.5. Europe Orphan Drugs Market Snapshot
  • 8.5.1. U.K. Orphan Drugs Market
  • 8.5.2. Germany Orphan Drugs Market
  • 8.5.3. France Orphan Drugs Market
  • 8.5.4. Spain Orphan Drugs Market
  • 8.5.5. Italy Orphan Drugs Market
  • 8.5.6. Rest of Europe Orphan Drugs Market
• 8.6. Asia-Pacific Orphan Drugs Market Snapshot
  • 8.6.1. China Orphan Drugs Market
  • 8.6.2. India Orphan Drugs Market
  • 8.6.3. Japan Orphan Drugs Market
  • 8.6.4. Australia Orphan Drugs Market
  • 8.6.5. South Korea Orphan Drugs Market
  • 8.6.6. Rest of Asia Pacific Orphan Drugs Market
• 8.7. Latin America Orphan Drugs Market Snapshot
  • 8.7.1. Brazil Orphan Drugs Market
  • 8.7.2. Mexico Orphan Drugs Market
• 8.8. Middle East & Africa Orphan Drugs Market
  • 8.8.1. Saudi Arabia Orphan Drugs Market
  • 8.8.2. South Africa Orphan Drugs Market
  • 8.8.3. Rest of Middle East & Africa Orphan Drugs Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Alexion Pharmaceuticals Inc
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Bristol-Myers Squibb Company (Celgene Corporation)
  • 9.3.3. Novartis AG
  • 9.3.4. Pfizer Inc.
  • 9.3.5. F. Hoffmann-La Roche Ltd
  • 9.3.6. Takeda Pharmaceutical Company Limited
  • 9.3.7. Amgen Inc.
  • 9.3.8. Sanofi S.A
  • 9.3.9. Johnson & Johnson Pvt Ltd
  • 9.3.10. AstraZeneca Plc

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption